
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc's enterprise value is currently approximately $430 million, which presents a potential for significant upside of 8-10 times the current share price if its partnership with Novo unfolds successfully. The company is advancing multiple candidates in its pipeline, particularly with SEP-631 showing promising results in Phase 1 trials, while SEP-479 has exhibited preclinical efficacy comparable to leading therapies and demonstrated favorable safety profiles in toxicology studies. With the potential for SEP-631 to achieve blockbuster status akin to Xolair, the therapeutic promise of Septerna's diverse pipeline positions the company favorably within the biotechnology sector.
Bears say
Septerna Inc faces significant risks that negatively impact its stock outlook, primarily stemming from potential delays in the clinical development of its drug candidates, including SEP-631, which could hinder progress in bringing products to market. Additionally, setbacks in clinical trials could derail the advancement of key therapies, while partnership uncertainties, particularly with Novo Nordisk, heighten the risk of collaboration instability. Lastly, concerns regarding the ability to secure regulatory approvals, achieve market penetration expectations, and the possibility of long-term dilution add to the overall financial uncertainty surrounding the company.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares